Liraglutide: A Tracking Guide for the Daily GLP-1

Liraglutide was the GLP-1 receptor agonist that proved the category could deliver meaningful weight loss before semaglutide and tirzepatide raised the ceiling. It is still in use, still approved (as Victoza for type 2 diabetes and Saxenda for weight management), and for some people the daily-injection cadence is actually preferable to the weekly competitors.

What it does

Liraglutide is a GLP-1 receptor agonist with a fatty acid side chain that extends its half-life to roughly 13 hours, enough to support once-daily dosing. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite.

Compared with semaglutide, the half-life is shorter, the average weight loss in trials is smaller, and the side-effect profile washes out faster after stopping. Those last two points are sometimes features rather than bugs.

Typical protocol shape

Liraglutide is titrated. Saxenda protocols typically start at a low daily dose and increase weekly until reaching a maintenance dose, with the option to pause titration if side effects are intolerable. Injection is subcutaneous, rotating between abdomen, thigh, and upper arm. The titration schedule is on the prescribing information and should be followed with your clinician.

What to track daily

• Injection time, dose, and site
• Nausea on a 1 to 10 scale
• Appetite on a 1 to 10 scale
• Eating window and total intake (a rough kcal estimate or a photo log)
• Bowel movements and any constipation or diarrhea
• Heart rate, which can rise modestly on GLP-1s
• Hydration

What to track weekly

• Weight, on the same scale at the same time of day
• Waist measurement
• Average appetite score
• Days with significant nausea
• Any vomiting episodes, which warrant a call to your prescriber

Bloodwork worth doing

• HbA1c at baseline and every three months
• Fasting lipid panel
• Comprehensive metabolic panel, including kidney function
• Lipase if you have any abdominal symptoms, given the pancreatitis warning on the class

Realistic expectations

Average weight loss in liraglutide trials at maintenance dose runs noticeably below what semaglutide achieves, with significant variation across individuals. Some people respond well to liraglutide and not to weekly agents, or tolerate it better. The daily dosing means side effects do not accumulate the way they can with a long-half-life weekly drug, which is the main tradeoff worth thinking about.

Common mistakes

• Skipping titration steps to chase faster weight loss
• Eating the same volume despite reduced appetite and then wondering why nausea is severe
• Stopping abruptly and expecting weight to stay off
• Dehydration, which amplifies almost every side effect
• Comparing your trajectory to semaglutide or tirzepatide users instead of the liraglutide trial data

A tracking template

Per injection: timestamp, dose, site. Per day: nausea, appetite, intake estimate, bowel movements, heart rate, hydration. Per week: weight, waist, average scores, side-effect days. Per quarter: HbA1c, lipids, CMP. Peptid AI handles daily-dose cadence cleanly and will flag missed doses, which is the most common quiet failure mode of a daily injectable.

Bottom line

Liraglutide is the slower, more controllable GLP-1. If a weekly agent overshot you on side effects or did not work, it is a legitimate alternative worth tracking properly rather than dismissing as obsolete.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.